Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

23.52 -0.19 (-0.80%)
Streaming Delayed Price Updated: 1:04 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 552,965
Open 23.68
Bid (Size) 23.52 (6)
Ask (Size) 23.53 (5)
Prev. Close 23.71
Today's Range 23.37 - 23.74
52wk Range 18.08 - 24.34
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill

Performance

YTD
-1.71%
-1.71%
1 Month
-0.76%
-0.76%
3 Month
+6.38%
+6.38%
6 Month
+18.31%
+18.31%
1 Year
+24.77%
+24.77%

More News

Read More
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
From Exelixis, Inc.
Via Business Wire
What Analysts Are Saying About Exelixis Stock
Via Benzinga
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
Via Chartmill
2 Stocks Under $30 to Buy and Hold
Via The Motley Fool
Recap: Exelixis Q4 Earnings
Via Benzinga
Earnings Scheduled For February 6, 2024
Via Benzinga
3 Biotech Stocks to Buy on the Dip: March 2024
Via InvestorPlace
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
2 Biotech Stocks to Buy Hand Over Fist in March
Via The Motley Fool
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
Via InvestorPlace
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
The 3 Best Biotech Stocks to Buy in February 2024
Via InvestorPlace
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
3 Attractive Medical Stocks To Buy After Earnings
Via Talk Markets
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.